Redmile Group’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.3M | Sell |
261,508
-21,800
| -8% | -$594K | 0.55% | 24 |
|
|
2025
Q4 | $7.69M | Sell |
283,308
-43,700
| -13% | -$1.15M | 0.57% | 26 |
|
|
2025
Q3 | $8.46M | Sell |
327,008
-16,018
| -5% | -$371K | 0.82% | 25 |
|
|
2025
Q2 | $6.98M | Sell |
343,026
-247,149
| -42% | -$4.81M | 0.74% | 29 |
|
|
2025
Q1 | $10.7M | Sell |
590,175
-25,600
| -4% | -$572K | 1.01% | 23 |
|
|
2024
Q4 | $15.6M | Sell |
615,775
-41,400
| -6% | -$1.12M | 1.08% | 27 |
|
|
2024
Q3 | $22.3M | Sell |
657,175
-61,548
| -9% | -$2.35M | 1.32% | 28 |
|
|
2024
Q2 | $26.6M | Sell |
718,723
-177,731
| -20% | -$6.71M | 1.61% | 25 |
|
|
2024
Q1 | $37.6M | Sell |
896,454
-97,349
| -10% | -$4M | 1.38% | 28 |
|
|
2023
Q4 | $39.4M | Sell |
993,803
-642,135
| -39% | -$18.9M | 1.41% | 22 |
|
|
2023
Q3 | $45M | Sell |
1,635,938
-60,066
| -4% | -$1.88M | 2.14% | 10 |
|
|
2023
Q2 | $57.5M | Sell |
1,696,004
-183,735
| -10% | -$6.19M | 2.21% | 9 |
|
|
2023
Q1 | $67.6M | Sell |
1,879,739
-97,712
| -5% | -$4.22M | 2.93% | 9 |
|
|
2022
Q4 | $88.1M | Sell |
1,977,451
-7,700
| -0.4% | -$275K | 3.61% | 8 |
|
|
2022
Q3 | $55.8M | Sell |
1,985,151
-85,137
| -4% | -$2.61M | 2.16% | 14 |
|
|
2022
Q2 | $55.8M | Buy |
2,070,288
+24,019
| +1% | +$698K | 2.13% | 13 |
|
|
2022
Q1 | $69.7M | Sell |
2,046,269
-119,317
| -6% | -$3.81M | 2.18% | 12 |
|
|
2021
Q4 | $83.7M | Sell |
2,165,586
-877,712
| -29% | -$38.3M | 1.9% | 15 |
|
|
2021
Q3 | $164M | Buy |
3,043,298
+31,217
| +1% | +$1.46M | 2.87% | 10 |
|
|
2021
Q2 | $101M | Sell |
3,012,081
-375,707
| -11% | -$10.3M | 1.49% | 20 |
|
|
2021
Q1 | $69.8M | Buy |
3,387,788
+676,172
| +25% | +$15.5M | 0.98% | 39 |
|
|
2020
Q4 | $47.5M | Buy |
2,711,616
+722,416
| +36% | +$13M | 0.58% | 47 |
|
|
2020
Q3 | $29.5M | Sell |
1,989,200
-10,800
| -0.5% | -$127K | 0.54% | 47 |
|
|
2020
Q2 | $26M | Buy |
+2,000,000
| New | +$8.86M | 0.48% | 55 |
|
|
2015
Q4 | – | Sell |
-130,268
| Closed | -$20.6M | – | 60 |
|
|
2015
Q3 | $20.6M | Buy |
130,268
+128,084
| +5,865% | +$36.3M | 1.56% | 21 |
|
|
2015
Q2 | $826K | Sell |
2,184
-34,283
| -94% | -$13.6M | 0.07% | 54 |
|
|
2015
Q1 | $15.2M | Buy |
36,467
+34,727
| +1,996% | +$12.4M | 1.37% | 32 |
|
|
2014
Q4 | $476K | Buy |
+1,740
| New | +$433K | 0.05% | 47 |
|
|
2014
Q2 | – | Sell |
-57,596
| Closed | -$15.3M | – | 52 |
|
|
2014
Q1 | $15.3M | Buy |
57,596
+31,066
| +117% | +$11.9M | 1.82% | 25 |
|
|
2013
Q4 | $9.63M | Buy |
+26,530
| New | +$10.2M | 1.19% | 36 |
|
Other funds holding CLDX
KCM
VCM
CC
EP
Redmile Group's CLDX Position: Q1 2026 in Review
Redmile Group reduced its Celldex Therapeutics (CLDX) stake by 7.7% in Q1 2026, selling an estimated $594K and leaving 261,508 shares worth $8.3M. The position accounts for 0.55% of the portfolio, ranked #24.
Redmile Group first reported a position in CLDX in Q4 2013 and has held it in 30 quarters since. The position peaked at $164M in Q3 2021. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.
- Redmile Group held 261,508 shares of Celldex Therapeutics worth $8.3M as of Q1 2026.
- Redmile Group sold 21,800 Celldex Therapeutics shares in Q1 2026, an estimated $594K.
- Celldex Therapeutics made up 0.55% of Redmile Group's portfolio in Q1 2026, its #24 holding.
- Redmile Group first reported a position in Celldex Therapeutics in Q4 2013 and has held it in 30 quarters since.
- Redmile Group's Celldex Therapeutics position peaked at $164M in Q3 2021.
- 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.
Based on Redmile Group's 13F filing for Q1 2026, filed 15 May 2026.